Paul Long, MD
Internal Medicine · Hilton Head Island, SCNPI 1982798849
Payments from drug & device makers
Across 225 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$535
- Novartis$367
- Johnson & Johnson$322
- GSK$278
- Astellas Pharma US Inc$274
- Novo Nordisk$264
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,71098%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $535 |
| Novartis | 21 | $367 |
| Johnson & Johnson | 22 | $322 |
| GSK | 14 | $278 |
| Astellas Pharma US Inc | 12 | $274 |
| Novo Nordisk | 18 | $264 |
| Pfizer | 12 | $198 |
| E.r. Squibb & Sons, L.L.C. | 13 | $183 |
| Kowa Pharmaceuticals America, Inc. | 12 | $160 |
| Amarin Pharma, Inc. | 10 | $159 |
| Abbott | 8 | $149 |
| AbbVie(2 entities) | 8 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Esperion Therapeutics, Inc. | 4 | $69 |
| Vivus LLC | 4 | $60 |
| Eisai Inc. | 4 | $60 |
| Merck | 4 | $51 |
| Exact Sciences | 3 | $45 |
| Radius Health, Inc. | 3 | $40 |
| Dexcom, Inc. | 1 | $37 |
| Lilly USA, LLC | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Mylan Specialty L.p. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| PBG Puerto Rico LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$3,798 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 146 | $123,725 |
| OzempicSemaglutide | 50 | $70,596 |
| Repatha SureclickEvolocumab | 67 | $59,390 |
| MounjaroTirzepatide | 51 | $54,613 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $39,556 |
| XareltoRivaroxaban | 37 | $32,655 |
| LinzessLinaclotide | 31 | $29,275 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $22,338 |
| JanuviaSitagliptin Phosphate | 16 | $15,683 |
| FarxigaDapagliflozin Propanediol | 12 | $14,825 |
| TrintellixVortioxetine Hydrobromide | 16 | $11,206 |
| LivaloPitavastatin Calcium | 12 | $8,664 |
| Omega-3 Acid Ethyl Esters | 68 | $7,664 |
| MovantikNaloxegol Oxalate | 18 | $6,662 |
| InvokanaCanagliflozin | 12 | $5,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $198 | $125,154165 claims |
| Novo NordiskOzempic | $264 | $70,59650 claims |
| Lilly USA, LLCMounjaro | $37 | $54,61351 claims |
| GSKTrelegy Ellipta | $278 | $39,55649 claims |
| Johnson & JohnsonXarelto, Invokana | $322 | $38,25749 claims |
| AbbVieLinzess, Synthroid | $121 | $33,31675 claims |
| MerckJanuvia | $51 | $15,68316 claims |
| AstraZenecaFarxiga | $20 | $14,82512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $11,20616 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $160 | $8,66412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Hilton Head Island
- William BunnHilton Head Island$125K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.